Works about SORAFENIB

Results: 1711

Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients.

Published in:

Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-025-05828-x

By:

Barakat, Eman M. F.;
Kohla, Mohamed;
Dabees, Hossam;
Shousha, Hend Ibrahim;
Moustafa, Ehab F.;
El-Kassas, Mohamed;
Aziz, Mona Shoukry;
Elkhateeb, Eman;
Abdelaziz, Ashraf Omar;
Abdelmalek, Mohamed Omar;
Azmy, Aly;
Tawheed, Ahmed;
Aboganob, Walaa Mosaad;
Taha, Hossam;
Lithy, Rania;
Radwan, Ahmed;
Ghoraba, Dalia;
Sayed, Hamdy;
Nassief, Anwar;
Elhelbawy, Mostafa

Publication type:

Article

Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib.

Published in:

Liver International, 2018, v. 38, n. 9, p. 1655, doi. 10.1111/liv.13731

By:

Jeon, Mi Young;
Lee, Hye Won;
Kim, Beom Kyung;
Park, Jun Yong;
Kim, Do Young;
Ahn, Sang Hoon;
Han, Kwang‐Hyub;
Baek, Song‐Ee;
Kim, Hye Soo;
Kim, Seung Up;
Park, Mi Suk

Publication type:

Article

Validation of the albumin‐bilirubin grade‐based integrated model as a predictor for sorafenib‐failed hepatocellular carcinoma.

Published in:

Liver International, 2018, v. 38, n. 2, p. 321, doi. 10.1111/liv.13527

By:

Li, Chung‐Pin;
Su, Chien‐Wei;
Hou, Ming‐Chih;
Lee, Fa‐Yauh;
Lin, Han‐Chieh;
Lee, Pei‐Chang;
Huang, Yi‐Hsiang;
Huo, Teh‐Ia;
Chen, Yi‐Tzen;
Chao, Yee;
Lee, Mei‐Hsuan

Publication type:

Article

Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.

Published in:

Liver International, 2017, v. 37, n. 12, p. 1869, doi. 10.1111/liv.13491

By:

Costentin, Charlotte E.;
Decaens, Thomas;
Laurent, Alexis;
Nault, Jean‐Charles;
Paule, Bernard;
Letoublon, Christian;
Luciani, Alain;
Calderaro, Julien;
Adam, René;
Bricault, Ivan;
Amaddeo, Giuliana;
Cherqui, Daniel;
Mallat, Ariane;
Samuel, Didier;
Duvoux, Christophe;
Ganne‐Carrié, Nathalie;
Roudot‐Thoraval, Françoise;
Vibert, Eric

Publication type:

Article

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.

Published in:

Liver International, 2017, v. 37, n. 7, p. 1047, doi. 10.1111/liv.13359

By:

Meyer, Tim;
Palmer, Daniel H.;
Cheng, Ann ‐ Lii;
Hocke, Julia;
Loembé, Arsène ‐ Bienvenu;
Yen, Chia ‐ Jui

Publication type:

Article

A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.

Published in:

Liver International, 2016, v. 36, n. 12, p. 1821, doi. 10.1111/liv.13170

By:

Edeline, Julien;
Blanc, Jean ‐ Frédéric;
Johnson, Philip;
Campillo ‐ Gimenez, Boris;
Ross, Paul;
Ma, Yuk Ting;
King, Judy;
Hubner, Richard A.;
Sumpter, Kate;
Darby, Suzanne;
Evans, Jeff;
Iwuji, Chinenye;
Swinson, Daniel;
Collins, Peter;
Patel, Kinnari;
Muazzam, Iqtedar;
Palmer, Daniel H.;
Meyer, Tim

Publication type:

Article

Is radioembolization or sorafenib the best option for patients with hepatocellular carcinoma and portal vein invasion?

Published in:

Liver International, 2016, v. 36, n. 11, p. 1715, doi. 10.1111/liv.13208

By:

Liao, Ying ‐ Yang;
Zhong, Jian ‐ Hong;
Peng, Ning ‐ Fu;
Li, Le ‐ Qun;
Tong, Tie ‐ Jun

Publication type:

Article

Response to Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy by Borentain et al.

Published in:

Liver International, 2016, v. 36, n. 9, p. 1394, doi. 10.1111/liv.13199

By:

Finkenstedt, Armin;
Zoller, Heinz

Publication type:

Article

Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.

Published in:

Liver International, 2016, v. 36, n. 8, p. 1196, doi. 10.1111/liv.13096

By:

Kudo, Masatoshi;
Lencioni, Riccardo;
Marrero, Jorge A.;
Venook, Alan P.;
Bronowicki, Jean ‐ Pierre;
Chen, Xiao ‐ Ping;
Dagher, Lucy;
Furuse, Junji;
Geschwind, Jean ‐ Francois H.;
Ladrón de Guevara, Laura;
Papandreou, Christos;
Sanyal, Arun J.;
Takayama, Tadatoshi;
Yoon, Seung Kew;
Nakajima, Keiko;
Lehr, Robert;
Heldner, Stephanie;
Ye, Sheng ‐ Long

Publication type:

Article

A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.

Published in:

Liver International, 2016, v. 36, n. 8, p. 1206, doi. 10.1111/liv.13098

By:

Torre, Manuel A.;
Buades ‐ Mateu, Juan;
Rosa, Pedro A.;
Lué, Alberto;
Bustamante, Francisco J.;
Serrano, María T.;
Testillano, Milagros;
Lorente, Sara;
Arenas, Juan I.;
Gil, Cristina;
Iñarrairaegui, Mercedes;
Sangro, Bruno

Publication type:

Article

Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.

Published in:

Liver International, 2016, v. 36, n. 7, p. 1033, doi. 10.1111/liv.13052

By:

Ponziani, Francesca Romana;
Bhoori, Sherrie;
Germini, Alessandro;
Bongini, Marco;
Flores, Maria;
Sposito, Carlo;
Facciorusso, Antonio;
Gasbarrini, Antonio;
Mazzaferro, Vincenzo

Publication type:

Article

Determination of the Anticancer Drug Sorafenib in Serum by Adsorptive Stripping Differential Pulse Voltammetry Using a Chitosan/Multiwall Carbon Nanotube Modified Glassy Carbon Electrode.

Published in:

Electroanalysis, 2016, v. 28, n. 2, p. 358, doi. 10.1002/elan.201500384

By:

Karadas‐Bakirhan, Nurgul;
Patris, Stéphanie;
Ozkan, Sibel A.;
Can, Alp;
Kauffmann, Jean‐Michel

Publication type:

Article

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Published in:

Journal of Neuro-Oncology, 2018, v. 136, n. 1, p. 79, doi. 10.1007/s11060-017-2624-4

By:

Nghiemphu, Phioanh Leia;
Ebiana, Victoria Asuquo;
Wen, Patrick;
Gilbert, Mark;
Abrey, Lauren E.;
Lieberman, F.;
DeAngelis, Lisa M.;
Robins, H. Ian;
Yung, W. K. Alfred;
Chang, Susan;
Drappatz, Jan;
Mehta, Minesh P.;
Levin, Victor A.;
Aldape, Kenneth;
Dancey, Janet E.;
Wright, J. J.;
Prados, Michael;
Kuhn, John;
Cloughesy, Timothy F.

Publication type:

Article

A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.

Published in:

Journal of Neuro-Oncology, 2017, v. 133, n. 2, p. 435, doi. 10.1007/s11060-017-2455-3

By:

Arneson, Kyle;
Mondschein, Joshua;
Stavas, Mark;
Cmelak, Anthony;
Attia, Albert;
Horn, Leora;
Niermann, Kenneth;
Puzanov, Igor;
Chakravarthy, A.;
Xia, Fen

Publication type:

Article

RNA-binding protein Dnd1 inhibits epithelial-mesenchymal transition and cancer stem cell-related traits on hepatocellular carcinoma cells.

Published in:

Biotechnology Letters, 2017, v. 39, n. 9, p. 1359, doi. 10.1007/s10529-017-2375-5

By:

Xu, Weiling;
Gong, Fangchao;
Zhang, Ting;
Chi, Baorong;
Wang, Jingyu

Publication type:

Article

Long Noncoding RNA E2F1 Messenger RNA Stabilizing Factor (EMS) Promotes Sorafenib Resistance in Renal Cell Carcinoma by Regulating miR‐363‐3p and Dual‐Specificity Phosphatase 10 Expression.

Published in:

Journal of Biochemical & Molecular Toxicology, 2025, v. 39, n. 3, p. 1, doi. 10.1002/jbt.70153

By:

Wang, Pinxiao;
Deng, Qian;
Pan, Siyuan;
Dong, Weiping

Publication type:

Article

N-allyl quinoxaline derivative exhibited potent and selective cytotoxicity through EGFR/VEGFR-mediated apoptosis: In vitro and in vivo studies.

Published in:

Journal of Biochemical & Molecular Toxicology, 2024, v. 38, n. 4, p. 1, doi. 10.1002/jbt.23690

By:

Nafie, Mohamed S.;
Ali, Mohab A.;
Youssef, Magdy M.

Publication type:

Article

Exosomal miR‐93 derived from hepatocellular carcinoma cell promotes the sorafenib resistance of hepatocellular carcinoma through PTEN/PI3K/Akt pathway.

Published in:

Journal of Biochemical & Molecular Toxicology, 2024, v. 38, n. 3, p. 1, doi. 10.1002/jbt.23666

By:

Bao, Yuanpeng;
Xu, Song;
Zhou, Junjing;
Zhao, Chongyong;
Dai, Saimin;
Zhang, Yong;
Rao, Min

Publication type:

Article

l‐Methionine potentiates anticancer activity of Sorafenib by epigenetically altering DUSP3/ERK pathway in hepatocellular carcinoma.

Published in:

Journal of Biochemical & Molecular Toxicology, 2024, v. 38, n. 3, p. 1, doi. 10.1002/jbt.23663

By:

Pal, Swagata;
Kabeer, Shaheen Wasil;
Sharma, Shivam;
Tikoo, Kulbhushan

Publication type:

Article

MiR‐600 mediates EZH2/RUNX3 signal axis to modulate breast cancer cell viability and sorafenib sensitivity.

Published in:

Journal of Biochemical & Molecular Toxicology, 2024, v. 38, n. 1, p. 1, doi. 10.1002/jbt.23613

By:

Zhao, Qian;
Li, Dan;
Feng, Jinchun;
Jinsihan, Dilixiati

Publication type:

Article

Upregulation of lncRNA PTOV1‐AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR‐505.

Published in:

Journal of Biochemical & Molecular Toxicology, 2023, v. 37, n. 10, p. 1, doi. 10.1002/jbt.23437

By:

Chi, Xiaobin;
Chen, Zhijian;
Chen, Yongbiao;
Hong, Hanyin;
Yu, Jianda;
Lv, Lizhi

Publication type:

Article

Retrospective evaluation of the effect of Ninjin'yoeito in hepatocellular carcinoma patients treated with lenvatinib.

Published in:

Surgery Today, 2022, v. 52, n. 3, p. 441, doi. 10.1007/s00595-021-02358-7

By:

Toshida, Katsuya;
Itoh, Shinji;
Yoshizumi, Tomoharu;
Shimagaki, Tomonari;
Wang, Huanlin;
Kurihara, Takeshi;
Toshima, Takeo;
Nagao, Yoshihiro;
Harada, Noboru;
Hata, Kojiro;
Makihara, Yoko;
Watanabe, Hiroyuki;
Mori, Masaki

Publication type:

Article

Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.

Published in:

Surgery Today, 2018, v. 48, n. 4, p. 431, doi. 10.1007/s00595-017-1603-x

By:

Takeyama, Hideaki;
Beppu, Toru;
Higashi, Takaaki;
Kaida, Takayoshi;
Arima, Kota;
Taki, Katsunobu;
Imai, Katsunori;
Nitta, Hidetoshi;
Hayashi, Hiromitsu;
Nakagawa, Shigeki;
Okabe, Hirohisa;
Hashimoto, Daisuke;
Chikamoto, Akira;
Ishiko, Takatoshi;
Tanaka, Motohiko;
Sasaki, Yutaka;
Baba, Hideo

Publication type:

Article

Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib.

Published in:

Pediatric Surgery International, 2022, v. 38, n. 3, p. 465, doi. 10.1007/s00383-021-05043-5

By:

Yang, Dou;
Chen, Feng;
Gong, Dan;
Zeng, Lei;
Xiang, Deng;
He, Yuanqiao;
Chen, Leifeng;
Yan, Jinlong;
Zhang, Shouhua

Publication type:

Article

Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib.

Published in:

2021

By:

Colagrande, S.;
Calistri, L.;
Campani, C.;
Dragoni, G.;
Lorini, C.;
Nardi, C.;
Castellani, A.;
Marra, F.

Publication type:

Correction Notice

Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.

Published in:

2021

By:

Doemel, Luzie A.;
Chapiro, Julius;
Laage Gaupp, Fabian;
Savic, Lynn Jeanette;
Kucukkaya, Ahmet S.;
Petukhova, Alexandra;
Tefera, Jonathan;
Zeevi, Tal;
Lin, MingDe;
Schlachter, Todd;
Jaffe, Ariel;
Strazzabosco, Mario;
Patel, Timil;
Stein, Stacey M.

Publication type:

journal article

CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib.

Published in:

European Radiology, 2021, v. 31, n. 3, p. 1608, doi. 10.1007/s00330-020-07171-3

By:

Colagrande, S.;
Calistri, L.;
Campani, C.;
Dragoni, G.;
Lorini, C.;
Nardi, C.;
Castellani, A.;
Marra, F.

Publication type:

Article

The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.

Published in:

European Radiology, 2021, v. 31, n. 1, p. 232, doi. 10.1007/s00330-020-07078-z

By:

Zhang, Yingqiang;
Miao, Hongfei;
Xie, Wenlin;
Jiang, Suxiang;
Song, Ze;
Huang, Guihua;
Fan, Wenzhe;
Wang, Yu;
Li, Jiaping;
Chen, Yong

Publication type:

Article

Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma.

Published in:

2018

By:

Choi, Jin Woo;
Chung, Jin Wook;
Lee, Dong Ho;
Kim, Hyo-Cheol;
Hur, Saebeom;
Lee, Myungsu;
Jae, Hwan Jun

Publication type:

journal article

Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging.

Published in:

2018

By:

Lee, Seunghyun;
Kim, Jung Hoon;
Lee, Jae Hwan;
Lee, Jeong Hwa;
Han, Joon Koo

Publication type:

journal article

Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.

Published in:

2017

By:

Gorodetski, Boris;
Chapiro, Julius;
Schernthaner, Ruediger;
Duran, Rafael;
Lin, MingDe;
Lee, Howard;
Lenis, David;
Stuart, Elizabeth;
Nonyane, Bareng;
Pekurovsky, Vasily;
Tamrazi, Anobel;
Gebauer, Bernhard;
Schlachter, Todd;
Pawlik, Timothy;
Geschwind, Jean-Francois;
Stuart, Elizabeth A;
Nonyane, Bareng Aletta Sanny;
Pawlik, Timothy M

Publication type:

journal article

Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.

Published in:

Oncology, 2025, v. 103, n. 6, p. 456, doi. 10.1159/000541018

By:

Persano, Mara;
Casadei-Gardini, Andrea;
Tada, Toshifumi;
Suda, Goki;
Shimose, Shigeo;
Kudo, Masatoshi;
Rossari, Federico;
Yoo, Changhoon;
Cheon, Jaekyung;
Finkelmeier, Fabian;
Lim, Ho Yeong;
Presa, José;
Masi, Gianluca;
Bergamo, Francesca;
Amadeo, Elisabeth;
Vitiello, Francesco;
Kumada, Takashi;
Sakamoto, Naoya;
Iwamoto, Hideki;
Aoki, Tomoko

Publication type:

Article

Varying Impact of Lenvatinib or Sorafenib Therapy on Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma.

Published in:

Oncology, 2024, v. 102, n. 9, p. 794, doi. 10.1159/000536501

By:

Yamauchi, Yurika;
Saeki, Issei;
Fujisawa, Koichi;
Egusa, Maho;
Nishiyama, Natsuko;
Fujioka, Tsuyoshi;
Kawamoto, Daiki;
Sasaki, Ryo;
Nishimura, Tatsuro;
Tanabe, Norikazu;
Hisanaga, Takuro;
Matsumoto, Toshihiko;
Ishikawa, Tsuyoshi;
Yamasaki, Takahiro;
Takami, Taro

Publication type:

Article

Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.

Published in:

Oncology, 2024, v. 102, n. 3, p. 239, doi. 10.1159/000533859

By:

Kikugawa, Chihiro;
Uchikawa, Shinsuke;
Kawaoka, Tomokazu;
Kinami, Takahiro;
Yano, Shigeki;
Amioka, Kei;
Naruto, Kensuke;
Ando, Yuwa;
Yamaoka, Kenji;
Tsuge, Masataka;
Kosaka, Yumi;
Ohya, Kazuki;
Mori, Nami;
Takaki, Shintaro;
Tsuji, Keiji;
Kouno, Hirotaka;
Kohno, Hiroshi;
Morio, Kei;
Moriya, Takashi;
Nonaka, Michihiro

Publication type:

Article

Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.

Published in:

Oncology, 2021, v. 99, n. 8, p. 491, doi. 10.1159/000515280

By:

Naruto, Kensuke;
Kawaoka, Tomokazu;
Amioka, Kei;
Ogawa, Yutaro;
Chihiro, Kikukawa;
Yoshikawa, Yuki;
Ando, Yuwa;
Suehiro, Yosuke;
Kosaka, Yumi;
Uchikawa, Shinsuke;
Kodama, Kenichiro;
Morio, Kei;
Fujino, Hatsue;
Murakami, Eisuke;
Nakahara, Takashi;
Yamauchi, Masami;
Tsuge, Masataka;
Hiramatsu, Akira;
Fukuhara, Takayuki;
Takaki, Shintaro

Publication type:

Article

Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors.

Published in:

Oncology, 2020, v. 98, n. 10, p. 727, doi. 10.1159/000507815

By:

Uchikawa, Shinsuke;
Kawaoka, Tomokazu;
Ando, Yuwa;
Yamaoka, Kenji;
Kosaka, Yumi;
Suehiro, Yosuke;
Fujii, Yasutoshi;
Morio, Kei;
Nakahara, Takashi;
Murakami, Eisuke;
Tsuge, Masataka;
Hiramatsu, Akira;
Imamura, Michio;
Takahashi, Shoichi;
Chayama, Kazuaki;
Aikata, Hiroshi

Publication type:

Article

Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion.

Published in:

Oncology, 2020, v. 98, n. 9, p. 621, doi. 10.1159/000507051

By:

Tanaka, Taku;
Kuzuya, Teiji;
Ishigami, Masatoshi;
Ito, Takanori;
Ishizu, Yoji;
Honda, Takashi;
Ishikawa, Tetsuya;
Fujishiro, Mitsuhiro

Publication type:

Article

Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells.

Published in:

Oncology, 2020, v. 98, n. 7, p. 478, doi. 10.1159/000505521

By:

Dattachoudhury, Sreeja;
Sharma, Renu;
Kumar, Atul;
Jaganathan, Bithiah Grace

Publication type:

Article

Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.

Published in:

Oncology, 2019, v. 97, n. 5, p. 277, doi. 10.1159/000501281

By:

Hiraoka, Atsushi;
Kumada, Takashi;
Atsukawa, Masanori;
Hirooka, Masashi;
Tsuji, Kunihiko;
Ishikawa, Toru;
Takaguchi, Koichi;
Kariyama, Kazuya;
Itobayashi, Ei;
Tajiri, Kazuto;
Shimada, Noritomo;
Shibata, Hiroshi;
Ochi, Hironori;
Tada, Toshifumi;
Toyoda, Hidenori;
Nouso, Kazuhiro;
Tsutsui, Akemi;
Nagano, Takuya;
Itokawa, Norio;
Hayama, Korenobu

Publication type:

Article

Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.

Published in:

Oncology, 2018, v. 95, n. 2, p. 91, doi. 10.1159/000488453

By:

Kuzuya, Teiji;
Ishigami, Masatoshi;
Ishizu, Yoji;
Honda, Takashi;
Hayashi, Kazuhiko;
Ishikawa, Tetsuya;
Nakano, Isao;
Hirooka, Yoshiki;
Goto, Hidemi

Publication type:

Article

A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.

Published in:

Oncology, 2018, v. 94, n. 6, p. 329, doi. 10.1159/000485384

By:

Thomas, Melanie B.;
Garrett-Mayer, Elizabeth;
Anis, Munazza;
Anderton, Kate;
Bentz, Tricia;
Edwards, Andie;
Brisendine, Alan;
Weiss, Geoffrey;
Siegel, Abby B.;
Bendell, Johanna;
Baron, Ari;
Duddalwar, Vinay;
El-Khoueiry, Anthony

Publication type:

Article

Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.

Published in:

Oncology, 2018, v. 94, n. 4, p. 215, doi. 10.1159/000486483

By:

Kodama, Kenichiro;
Kawaoka, Tomokazu;
Aikata, Hiroshi;
Uchikawa, Shinsuke;
Nishida, Yuno;
Inagaki, Yuki;
Hatooka, Masahiro;
Morio, Kei;
Nakahara, Takashi;
Murakami, Eisuke;
Tsuge, Masataka;
Hiramatsu, Akira;
Imamura, Michio;
Kawakami, Yoshiiku;
Masaki, Keiichi;
Honda, Yoji;
Mori, Nami;
Takaki, Shintaro;
Tsuji, Keiji;
Kohno, Hirotaka

Publication type:

Article

Systemic Therapy for Hepatocellular Carcinoma: 2017 Update.

Published in:

Oncology, 2017, v. 93, p. 135, doi. 10.1159/000481244

By:

Kudo, Masatoshi

Publication type:

Article

Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).

Published in:

Oncology, 2017, v. 93, p. 127, doi. 10.1159/000481243

By:

Kudo, Masatoshi;
Arizumi, Tadaaki

Publication type:

Article

Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.

Published in:

Oncology, 2017, v. 93, p. 113, doi. 10.1159/000481241

By:

Ogawa, Chikara;
Morita, Masahiro;
Omura, akina;
Noda, Teruyo;
Kubo, atsushi;
Matsunaka, Toshihiro;
Tamaki, Hiroyuki;
Shibatoge, Mitsushige;
Tsutsui, akemi;
Senoh, Tomonori;
Nagano, Takuya;
Takaguchi, Kouichi;
Tani, Joji;
Morishita, asahiro;
Yoneyama, Hirohito;
Masaki, Tsutomu;
Moriya, akio;
ando, Masaharu;
Deguchi, akihiro;
Kokudo, Yasutaka

Publication type:

Article

Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.

Published in:

Oncology, 2017, v. 92, n. 6, p. 335, doi. 10.1159/000458532

By:

Kawaoka, Tomokazu;
Aikata, Hiroshi;
Teraoka, Yuji;
Inagaki, Yuki;
Honda, Fumi;
Hatooka, Masahiro;
Morio, Kei;
Morio, Reona;
Kobayashi, Tomoki;
Nagaoki, Yuko;
Nakahara, Takashi;
Hiramatsu, Akira;
Tsuge, Masataka;
Imamura, Michio;
Kawakami, Yoshiiku;
Chayama, Kazuaki

Publication type:

Article

Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma.

Published in:

Oncology, 2016, v. 91, n. 5, p. 261, doi. 10.1159/000449000

By:

Kuzuya, Teiji;
Ishigami, Masatoshi;
Ishizu, Yoji;
Honda, Takashi;
Hayashi, Kazuhiko;
Ishikawa, Tetsuya;
Nakano, Isao;
Goto, Hidemi;
Hirooka, Yoshiki

Publication type:

Article

Absorption, distribution, metabolism and excretion (ADME) of sorafenib and its two analogues of 2- aminoquinolone, in rat animal model, in silico -- in vivo interplay.

Published in:

Journal of Research in Pharmacy, 2025, v. 29, n. 3, p. 1239, doi. 10.12991/jrespharm.1633820

By:

IDKAIDEK, Nasir M.;
SALEH, Hiba;
WADI, Noor;
Al-SHEIKH, Ahmad;
QINNA, Nidal;
ALDABET, Gaida;
RABAYIA, Ayman;
TUFFAHA, Haya;
ALSHOAIBI, Laith;
ALGHAZAWI, Ahmad

Publication type:

Article

Systemic treatment of patients with advanced hepatocellular carcinoma.

Published in:

Oncology in Clinical Practice (2450-1654), 2021, v. 17, n. 4, p. 164, doi. 10.5603/OCP.2020.0047

By:

Potemski, Piotr

Publication type:

Article

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.

Published in:

JAMA Network Open, 2021, v. 4, n. 4, p. e214846, doi. 10.1001/jamanetworkopen.2021.4846

By:

Zhang, Xin;
Wang, Jingjing;
Shi, Juanjuan;
Jia, Xiaoli;
Dang, Shuangsuo;
Wang, Wenjun

Publication type:

Article